COVERAGE / GILD / Healthcare

GILEAD SCIENCES, INC.

Biological Products, (No Diagnostic Substances)

COVERAGE STATUSACTIVE

DATA THROUGH2025-12-31

RESEARCH REPORTS1

SELECTED FILINGS1

Fundamental matrix

Latest / 2025-12-31 · Prior / 2024-12-31 · USD · Annual periods

Revenue

$29.44bn

Prior / $28.75bn

Change / +2.40%

SOURCE / 2026-02-24

Operating income

$10.02bn

Prior / $1.66bn

Change / +503.01%

SOURCE / 2026-02-24

Net income

$8.51bn

Prior / $0.48bn

Change / +1672.92%

SOURCE / 2026-02-24

Diluted EPS

$6.78

Prior / $0.38

Change / +1684.21%

SOURCE / 2026-02-24

Free cash flow

$9.46bn

Prior / $10.31bn

Change / -8.24%

SOURCE / 2026-02-24

Gross margin

Not available

Prior / Not available

Change / Unavailable

SOURCE / Not available

Operating margin

34.04%

Prior / 5.78%

Change / +28.26 pp

SOURCE / 2026-02-24

Return on avg. equity

40.49%

Prior / 2.28%

Change / +38.22 pp

SOURCE / 2026-02-24

Debt / equity

Not available

Prior / Not available

Change / Unavailable

SOURCE / Not available

ROE uses net income divided by average opening/closing equity. FCF = operating cash flow − selected capital expenditure. Debt/equity is unavailable because a verified interest-bearing-debt series is absent; total liabilities are not substituted for debt.

Inspect source tags, dates and accession numbers

{
  "revenue": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 29443000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
    "unit": "USD"
  },
  "netIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 8510000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "us-gaap:NetIncomeLoss",
    "unit": "USD"
  },
  "operatingIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 10022000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "us-gaap:OperatingIncomeLoss",
    "unit": "USD"
  },
  "eps": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 6.78,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "us-gaap:EarningsPerShareDiluted",
    "unit": "USD/shares"
  },
  "operatingCashFlow": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 10019000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
    "unit": "USD"
  },
  "capex": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 563000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment",
    "unit": "USD"
  },
  "totalAssets": {
    "end": "2025-12-31",
    "val": 59023000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "tag": "us-gaap:Assets",
    "unit": "USD"
  },
  "shareholdersEquity": {
    "end": "2025-12-31",
    "val": 22703000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "tag": "us-gaap:StockholdersEquity",
    "unit": "USD"
  },
  "currentAssets": {
    "end": "2025-12-31",
    "val": 18342000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "tag": "us-gaap:AssetsCurrent",
    "unit": "USD"
  },
  "currentLiabilities": {
    "end": "2025-12-31",
    "val": 11813000000,
    "accn": "0000882095-26-000006",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-24",
    "tag": "us-gaap:LiabilitiesCurrent",
    "unit": "USD"
  }
}

Financial trend system

Annual financial trends are summarized in the accessible table below.

Annual figures / accessible table

Period end	Revenue	Net income	Free cash flow	EPS
2025-12-31	$29.44bn	$8.51bn	$9.46bn	$6.78
2024-12-31	$28.75bn	$0.48bn	$10.31bn	$0.38
2023-12-31	$27.12bn	$5.67bn	$7.42bn	$4.50
2022-12-31	$27.28bn	$4.59bn	$8.34bn	$3.64

Valuation context

Historical snapshot / 2026-09-17. Annual accounting period / 2025-12-31. Not current, TTM or forward valuation.

Dated ratios / eligible same-method sector sample
Measure	Snapshot value	Historical median	Sector median	Peer count
P/E	22.26x	Unavailable	27.08x	10
P/S	6.35x	Unavailable	6.63x	10
P/B	8.24x	Unavailable	7.31x	8
EV / EBITDA	Unavailable	Unavailable	Unavailable	0
FCF yield	5.05%	Unavailable	3.88%	8

Annual denominators, not TTM or forward. Capitalization-based measures use estimated market capitalization from the dated quote snapshot. ADR/share-basis uncertainty is excluded. No comparable historical-multiple series or EV/EBITDA is available. Sector samples are equal-weight medians of this publication’s eligible covered companies; fiscal periods differ. No fair value or price target is implied.

Source: Yahoo Finance completed daily-bar snapshot; not live; market cap estimated using SEC shares at 2026-07-31 DAILY-BAR SOURCE ↗

Retained price snapshot and capitalization estimate

{
  "currentPrice": 150.89,
  "tradingDate": "2026-09-17",
  "marketCap": 187096833337.95,
  "source": "Yahoo Finance completed daily-bar snapshot; not live; market cap estimated using SEC shares at 2026-07-31"
}

Company & operating context

GILEAD SCIENCES, INC. is an SEC-reporting issuer listed on NASDAQ under GILD. Its SEC industry description is Biological Products, (No Diagnostic Substances). This profile organizes annual financial disclosures for research; sector labels are editorial groupings, not GICS classifications.

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Segment-level revenue is not included in this standardized dataset. Consult the business and segment notes in the linked annual filing for the issuer’s actual reporting segments.

Filing timeline

10-KFILED / 2026-02-24PERIOD / 2025-12-31

GILD filed this 10-K on 2026-02-24 for the reported period 2025-12-31. Reading focus: Product concentration, research investment, utilization, reimbursement and cash generation. This is a metadata-based reading guide; it does not assert that a particular event or risk change occurred in the document.

ORIGINAL SEC DISCLOSURE ↗

Research archive

HR-0067GILDCompany Research

GILD: reading the FY2025 financial structure ↗

GILEAD SCIENCES, INC.

Research abstract

Annual revenue of USD 29.443 billion and net income of USD 8.510 billion for the period ended 2025-12-31.

DATA THROUGH2025-12-312 MIN READPUBLISHED 2026-09-26

Sector context & risk factors

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.

Product concentration, research investment, utilization, reimbursement and cash generation.

HEALTHCARE SYSTEM ↗

Sources & dates

SEC annual filing · 2025-12-31 ↗Source date 2026-02-24
SEC annual filing · 2024-12-31 ↗Source date 2026-02-24
SEC annual filing · 2023-12-31 ↗Source date 2026-02-24
SEC annual filing · 2022-12-31 ↗Source date 2025-02-28
SEC issuer record ↗Source date 2026-09-18